tiprankstipranks
Advertisement
Advertisement
Harrison Lifts JBIO Price Target to $74 on Promising JADE101 Data and Attractive IgA Nephropathy Opportunity
PremiumRatingsHarrison Lifts JBIO Price Target to $74 on Promising JADE101 Data and Attractive IgA Nephropathy Opportunity
9d ago
Akash Tewari Initiates Buy on JBIO, Citing Strong Early JADE101 Data, Clean Safety Profile, and Significant IgA Nephropathy Commercial Upside
Premium
Ratings
Akash Tewari Initiates Buy on JBIO, Citing Strong Early JADE101 Data, Clean Safety Profile, and Significant IgA Nephropathy Commercial Upside
10d ago
Jefferies says Jade Biosciences JADE101 data came in line with bull case
Premium
The Fly
Jefferies says Jade Biosciences JADE101 data came in line with bull case
10d ago
Jade Biosciences announces first participant dosed in JADE201 Phase 1 trial
PremiumThe FlyJade Biosciences announces first participant dosed in JADE201 Phase 1 trial
16d ago
Jade Biosciences announces first participant dosed in Phase 2 Juniper trial
Premium
The Fly
Jade Biosciences announces first participant dosed in Phase 2 Juniper trial
16d ago
Arthur He Reiterates Buy on Jade with Unchanged $45 Price Target Ahead of Key JADE101 Phase 1 Data
Premium
Ratings
Arthur He Reiterates Buy on Jade with Unchanged $45 Price Target Ahead of Key JADE101 Phase 1 Data
1M ago
Jade Biosciences files $600M mixed securities shelf
PremiumThe FlyJade Biosciences files $600M mixed securities shelf
1M ago
Jade Biosciences files to sell 39.54M shares of common stock for holders
Premium
The Fly
Jade Biosciences files to sell 39.54M shares of common stock for holders
1M ago
Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright
Premium
The Fly
Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100